Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Clinician Input Needed: Do You Prescribe GLP-1 Receptor Agonists?
Are your patients asking about Ozempic and other GLP-1RAs? Are you prescribing it? Take our quick survey.
©Peter Hansen/stock.adobe.com
The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of overweight and obesity marks one of medicine's most revolutionary shifts in decades. These medicines are popularly known to patients as brands including Ozempic or Wegovy.
We value your expertise! We're conducting a brief survey to gather insights from clinicians of all backgrounds on the use and perceptions of GLP-1RAs for managing obesity.
Your feedback will be instrumental in helping us create content to inform you and your colleagues about this rapidly developing space.
The survey takes only 5 minutes to complete, and all responses are anonymous.
Recent Videos
Related Content
